Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
216.18B
Market cap216.18B
Price-Earnings ratio
11.27
Price-Earnings ratio11.27
Dividend yield
2.56%
Dividend yield2.56%
Average volume
13.36M
Average volume13.36M
High today
$48.50
High today$48.50
Low today
$46.70
Low today$46.70
Open price
$47.03
Open price$47.03
Volume
20.14M
Volume20.14M
52 Week high
$71.80
52 Week high$71.80
52 Week low
$35.12
52 Week low$35.12

NVO News

Nasdaq 1d
Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly?

Key Points Eli Lilly leads in next‑gen obesity drugs, while Novo Nordisk offers a cheaper, dividend‑paying alternative. Novo’s steady insulin cash flows and n...

Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly?
TipRanks 2d
Novo Nordisk Tests Cagrilintide in Patients Who Cannot Tolerate GLP-1 Weight-Loss Drugs

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more...

Nasdaq 2d
An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?

Key Points "The field is getting more crowded -- but Lilly is widening its lead,” said RBC analyst Trung Huynh. Until Novo Nordisk gets back to positive growt...

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?

Analyst ratings

54%

of 37 ratings
Buy
37.8%
Hold
54.1%
Sell
8.1%

More NVO News

The Motley Fool 3d
The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch

Investors looking to capitalize on the rapidly growing artificial intelligence (AI) industry tend to turn toward leading tech corporations. That's understandabl...

The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch
Simply Wall St 3d
Novo Nordisk Stock After Recent Pharma Sector Focus Is The Valuation Attractive

If you are wondering whether Novo Nordisk stock is starting to look attractively priced or still carries a premium, the current setup offers plenty of clues in...

Novo Nordisk Stock After Recent Pharma Sector Focus Is The Valuation Attractive
TipRanks 3d
Novo Nordisk Details Progress in DKK 15 Billion Share Buyback

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

24/7 Wall St. 4d
Forget Novo Nordisk. Pfizer's Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Pfizer didn't make the cut. Grab the names FREE today . Novo Nordisk's US...

Forget Novo Nordisk. Pfizer's Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait
Nasdaq 4d
NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push

Novo Nordisk NVO shares gained 6.2% on Monday after the Novo Nordisk Foundation, the controlling shareholder of the Danish drugmaker, unveiled a major pan-Europ...

NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push
Nasdaq 5d
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk

Key Points Viking Therapeutics has a weight-loss program that looks to be competitive with medicines already on the market. It's unclear how its candidate com...

Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk
Benzinga 5d
Novo Nordisk Stock Is Surging Monday: What's Driving The Action?

Novo Nordisk stock is showing exceptional strength. Why is NVO stock surging? What Is Driving Novo Nordisk’s Stock Rally? Novo Nordisk’s rally is landing in a m...

Novo Nordisk Stock Is Surging Monday: What's Driving The Action?

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.